The New Jersey car accident attorneys at Breslin and Breslin are reporting that Tesla Motors said Friday it is recalling all 90,000 Model S sedans produced to check for a possible defect in the front seat belt assemblies.
The personal injury attorneys at Breslin and Breslin would like to help spread the word of a chicken cutlet recall in New Jersey.
The New Jersey car accident attorneys at Breslin and Breslin are glad to announce that a new online search tool allowing you to check whether recall repairs have been completed on specific makes of cars, trucks, and motorcycles is now available. The free database, which is available on the National Highway Traffic Safety Administration's website, allows consumers to find out if the vehicle they are considering purchasing has any unaddressed safety issues. For the first time, car buyers will be able to enter the VIN (vehicle identification number) and learn almost instantaneously if that particular vehicle has been recalled.
Multiple news sources are reporting that persons closely familiar with the Johnson & Johnson (J&J) DePuy ASR hip implant litigation say that the New Jersey-based pharmaceutical giant has reached settlements with three plaintiffs in the first product liability lawsuits slated for trial in state court.
Last month, the U.S. Food and Drug Administration (FDA) proposed a policy which, if adopted, could significantly increase the oversight and safety of the medical device industry. Under the proposal, each individual device would receive its own identification number, allowing medical professionals and manufacturers to better track defective products, determine the cause of the problems and alert other patients who are using the same device.
Bergen County residents who have suffered injuries from faulty DePuy hip replacements or other defective Johnson & Johnson products will likely be interested to learn that J&J recently set aside $600 million in preparation for a potential settlement over kickbacks allegations. This is in addition to the $5.3 billion that has reportedly already been reserved for potential products liability and kickback claims in relation to other J&J medications and medical devices.
Earlier this week, the U.S. House of Representatives approved a bill that secures the funding for the Food and Drug Administration (FDA) for the next several years. Last week, the U.S. Senate passed a similar version of the bill, and leaders from the chambers will now work to come to a consensus, reportedly aiming for July 4 as a deadline to finalize the bill.
Last month, we wrote about federal legislators' efforts to close the loophole in the U.S. Food and Drug Administration's medical device approval process. Now, it appears that a top official with the device division of the FDA agrees that such a change should be made. Hopefully, this will spur the legislation and prevent dangerous or defective products from making it to the marketplace in the future.
After a string of product recalls and products liability lawsuits, the chief executive officer of Johnson & Johnson is reportedly stepping down from his position later this spring. Although the New Jersey company's revenue has doubled in the past decade, the many product recalls in recent years have reportedly cost Johnson & Johnson more than $1 billion, as well as the serious hits to its public image and consumers' trust.